Payal Sahni Becher is currently the Chief People Experience Officer & Executive VP at Pfizer Inc. She started this position in 2022. Prior to her current role, she obtained a graduate degree from ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

According to Benzinga Pro, Pfizer's peer group average for short interest as a percentage of float is 3.60%, which means the ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Shares of Pfizer Ltd are in news today rose after the firm reported a stellar set of Q4 earnings. The pharma firm reported a ...

Collin Brantmeyer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...